PTC Therapeutics, Inc. (PTCT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$69.30-2.94%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PTCT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -19.6% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 26.0% |
Growth built into the price is above our model estimate.
The price assumes 45.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
PTCT — director transition
Dated 2026-07-30
Director — Hege Sollie-Zetlmayer: Ms. Hege Sollie-Zetlmayer was appointed to the board of directors, filling a vacancy.
Why it matters: Buying back notes can help financial stability and lower debt.
Supportive ifPTC buys back $222 million in convertible notes as planned.
Worry ifPTC fails to execute the repurchase or delays it beyond Q3 2026.
Why it matters: Results will show how well votoplam works for Huntington's disease. This will affect future revenue.
Watch forPositive results from the Phase 3 INVEST-HD study show a big slowdown in disease progression.
Also watch forNegative results from the Phase 3 INVEST-HD study show no real benefit.
Why it matters: Keeping expenses between $680 million and $720 million shows they manage costs well.
Supportive ifReported R&D and SG&A expenses are at or below $680 million.
Worry ifReported R&D and SG&A expenses exceed $720 million.
Why it matters: An update on revenue guidance will show if the company is on track to meet its goals. This is key for investor confidence.
Supportive ifManagement raises total revenue guidance to $1.08 billion or more for 2026.
Worry ifManagement lowers total revenue guidance to less than $1.08 billion for 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$142 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $374 loss on $10,000 · 3.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,717 loss on $10,000 · 27.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: If revenue growth drops below its median, it signals a potential slowdown in the healthcare sector. This could impact PTC's performance.
Worry ifHealthcare revenue growth reported below the median of 1% year over year.
Less concerning ifHealthcare revenue growth remains above the median of 1% year over year.
Why it matters: Strong product revenue growth supports the raised guidance for 2026. This shows ongoing demand for Sephience and other products.
Supportive ifQ3 product revenue is over $239 million. This shows continued growth.
Worry ifQ3 product revenue falls below $239 million, suggesting a slowdown.
Why it matters: Updates on this study will show how well votoplam works. Good results could help PTC's stock.
Supportive ifPositive interim results from the Phase 3 study are out. They show strong effects in slowing disease.
Worry ifNegative results or delays in the study are reported.
Why it matters: Finishing this offering is important for PTC's finances. It may affect future investments.
Watch forThe offering is completed successfully. The money will be used for planned repurchases and other needs.
Also watch forFailure to complete the offering or a significant change in planned use of proceeds.
Why it matters: Sephience revenue growth shows strong market demand. This helps meet overall revenue goals.
Supportive ifSephience revenue grows over 20% from Q2 to Q3 in 2026.
Worry ifSephience revenue growth drops below 10% from Q2 to Q3 in 2026.
Why it matters: Study results could support PTC's R&D work and affect future products.
Watch forThe Phase 1 study of PTC612 shows it is safe and works well.
Also watch forThe Phase 1 study of PTC612 shows safety or effectiveness problems.
Why it matters: Staying in this range would show PTC is managing costs well as it grows.
Supportive ifQ3 2026 R&D expenses reported between $99 million and $110 million.
Worry ifR&D costs went over $115 million in Q3 2026. This may mean overspending.
Why it matters: Hitting this revenue would show that management's plans are working.
Supportive ifTotal revenue reported at or above $1.18 billion for 2026.
Worry ifTotal revenue was below $1.18 billion for 2026.
Why it matters: Starting this study is key for NDA resubmission. It shows PTC's commitment to advancing its pipeline.
Supportive ifThe PROVE-FA study begins as planned in Q3 2026.
Worry ifThe study is delayed or not initiated in Q3 2026.
Why it matters: Good feedback from the FDA could lead to approval for votoplam. This is key for future money.
Supportive ifThe FDA gives positive feedback on the PIVOT-HD results.
Worry ifThe FDA response is negative or asks for more data.
Why it matters: Enrollment progress is key for votoplam's long-term success. It shows the study is moving.
Watch forEnrollment hits or goes over 770 people as planned.
Also watch forEnrollment is far behind the target of 770 people.